1. Home
  2. MITT vs ACRS Comparison

MITT vs ACRS Comparison

Compare MITT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MITT
  • ACRS
  • Stock Information
  • Founded
  • MITT 2011
  • ACRS 2012
  • Country
  • MITT United States
  • ACRS United States
  • Employees
  • MITT N/A
  • ACRS N/A
  • Industry
  • MITT Real Estate Investment Trusts
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MITT Real Estate
  • ACRS Health Care
  • Exchange
  • MITT Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • MITT 204.8M
  • ACRS 165.7M
  • IPO Year
  • MITT 2011
  • ACRS 2015
  • Fundamental
  • Price
  • MITT $7.68
  • ACRS $1.43
  • Analyst Decision
  • MITT Strong Buy
  • ACRS Strong Buy
  • Analyst Count
  • MITT 4
  • ACRS 8
  • Target Price
  • MITT $8.50
  • ACRS $9.71
  • AVG Volume (30 Days)
  • MITT 253.8K
  • ACRS 1.3M
  • Earning Date
  • MITT 08-01-2025
  • ACRS 08-06-2025
  • Dividend Yield
  • MITT 10.38%
  • ACRS N/A
  • EPS Growth
  • MITT N/A
  • ACRS N/A
  • EPS
  • MITT 0.89
  • ACRS N/A
  • Revenue
  • MITT $79,955,000.00
  • ACRS $17,777,000.00
  • Revenue This Year
  • MITT N/A
  • ACRS N/A
  • Revenue Next Year
  • MITT $9.01
  • ACRS $11.77
  • P/E Ratio
  • MITT $8.67
  • ACRS N/A
  • Revenue Growth
  • MITT 13.91
  • ACRS N/A
  • 52 Week Low
  • MITT $5.63
  • ACRS $1.05
  • 52 Week High
  • MITT $7.95
  • ACRS $5.17
  • Technical
  • Relative Strength Index (RSI)
  • MITT 57.20
  • ACRS 46.21
  • Support Level
  • MITT $7.42
  • ACRS $1.34
  • Resistance Level
  • MITT $7.95
  • ACRS $1.66
  • Average True Range (ATR)
  • MITT 0.21
  • ACRS 0.10
  • MACD
  • MITT 0.01
  • ACRS -0.01
  • Stochastic Oscillator
  • MITT 67.47
  • ACRS 16.67

About MITT AG Mortgage Investment Trust Inc.

AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: